Unlisted Medicines and New Combinations: Verify Before Prescribing
Verify unlisted medicines with a worked evidence trail for pack details, conflicting formulations, clinical review and catalogue decisions.
When a chemist reports an unavailable medicine, capture the original prescription and the exact proposed alternative, including ingredients, strength, formulation, release characteristics and route. A clinician or appropriately authorised professional must review the change within the applicable rules. Record the decision, revise affected instructions and clarify what the patient actually received; similar names or dose arithmetic alone do not establish equivalence.
Indian clinic doctors, reception teams and pharmacists handling out-of-stock products, alternative strengths and supply-related prescription clarification.
“The usual brand is unavailable; can we give the other one?” hides several possible changes. The alternative may have the same ingredient and strength, a different strength, another release formulation or an additional ingredient. Before seeking a decision, identify what is actually being proposed and which prescription version the pharmacy is reading.
Reception can collect information and route the query without approving a clinical substitution. Record the caller’s role, pharmacy and callback route, the patient and prescription reference, the unavailable item and the proposed supply. Avoid collecting unrelated patient details over an unverified call.
If the product is unclear, request appropriate label or packaging information through the clinic’s agreed channel. Preserve uncertainty. A confident transcription of an incomplete brand name does not create evidence of the ingredients or formulation.
Read the ingredients and strengths from a reliable source, including every ingredient in a fixed-dose combination. Check the strength basis, dosage form, route and any modified-release or other formulation distinction. Device or administration requirements may also matter for products such as insulin and inhalers.
A matching ingredient does not resolve every suitability question. The clinician considers the intended indication, patient circumstances, the current regimen and the specific proposed product. This article does not establish a universal Indian legal authority for brand substitution or a rule permitting every pharmacy to change a prescription.
If the proposal is a different treatment because the original is unavailable, describe it as a new clinical decision. Calling it a substitution should not hide the need to reassess the plan, explain the change and update monitoring or follow-up where relevant.
NHS Specialist Pharmacy Service guidance identifies product information and brand-specific administration instructions as relevant when considering formulation changes. Its published context is swallowing difficulties in UK practice. Here it supports checking the actual presentation; it is not authority to apply UK substitution rules or manipulation instructions in an Indian clinic.
Source: NHS SPS: Checking if tablets can be crushed or capsules opened
This fictional case concerns a two-item prescription P1 issued by an Indian clinic. At 10:10, the chemist reports that the product on line 1 is unavailable locally; line 2 is not part of the query. The ingredient letters and proposal names below are teaching labels, not actual medicines. Real strengths, doses and treatment directions are deliberately omitted, so the example cannot be used as a prescription or an interchangeability list.
The clinic confirms the pharmacy callback route and the P1 version being read. At 10:25, it has three proposed product descriptions with readable labels and relevant manufacturer information for the reviewer. Proposal A has the original ingredient and printed strength but a different release formulation. Proposal B adds another active ingredient. Proposal C has a different brand name while matching the recorded ingredient, strength and its basis, tablet form, release characteristics and oral route.
The comparison below contains four rows because the original is the reference, followed by three proposals. It does not rank products by availability or price. Nor does it treat matching fields as sufficient evidence of clinical suitability: the responsible prescriber still evaluates the actual product information, current patient circumstances and intended treatment. If an identifying field remains unreadable, the reviewer should see that gap instead of a completed “same medicine” label.
In this fictional case, the prescriber authorises Proposal C for line 1 at 10:45 after that review. Proposals A and B are not authorised for this request. This is one patient-specific decision, not a general declaration that either proposal is always unsuitable or that every same-ingredient brand can be exchanged. A request to split, crush, open or otherwise alter a presentation would need its own product-specific review; no such manipulation is approved here.
On a narrow screen, scroll the table horizontally to read all columns.
| Product being compared | Identity evidence in this example | Difference requiring a decision |
|---|---|---|
| Original line 1 | Ingredient X; recorded strength per tablet; immediate-release tablet for oral use | Reference identity from P1; local unavailability is a reported supply problem |
| Proposal A | Ingredient X and the same printed strength; modified-release oral tablet | Release characteristics differ; equal printed strength does not settle the change |
| Proposal B | Ingredient X plus Ingredient Y; oral tablet | An additional active ingredient changes the proposed treatment; the original line cannot describe the whole product |
| Proposal C | Different brand; recorded ingredient, strength and its basis, tablet form, immediate release and oral route match | Matching fields support review but do not themselves authorise supply; exact C is accepted only after the fictional prescriber’s assessment |
Use this original query matrix to organise the handover. It helps the reviewer identify the missing evidence; it is not an equivalence table. Several rows can apply to the same proposed product, so do not force a complicated query into one reassuring category.
On a narrow screen, scroll the table horizontally to read all columns.
| Proposed change | Details to establish | Assumption to avoid |
|---|---|---|
| Different brand | Full identity, strength, formulation, route and relevant product information | The same leading ingredient guarantees the same instructions |
| Different strength | Clinician-approved amount, usable presentation and revised patient directions | Simple multiplication authorises a new regimen |
| Tablet splitting | Exact product labelling, suitability and ability to follow the reviewed plan | Every scored or similar-looking tablet can be split |
| Different release formulation | Release characteristics and clinical appropriateness | An equal printed strength makes formulations interchangeable |
| Combination instead of single ingredient | Every ingredient and overlap with current medicines | The familiar brand word means nothing else changed |
| Different delivery device | Exact presentation, patient ability and teaching needs | The old device instructions remain applicable |
| Partial supply | Quantity actually dispensed and the plan for the remainder | A smaller pack silently changes treatment duration |
A numerical relationship between strengths is not sufficient to approve a change. The formulation may not support splitting, the patient may struggle with the new instructions or the proposed product may differ in another important respect. First establish suitability and authorisation, then document the precise instruction the clinician approves.
FDA tablet-splitting guidance advises checking the specific product information and notes that many sustained, controlled or timed-release products are not intended for splitting, with exceptions only where supported by the product information. Its US regulatory context is not an Indian dispensing rule. The relevant lesson for this workflow is to verify the actual product rather than assuming that a score line or another brand’s behaviour settles the question.
A changed tablet count also affects how long a dispensed quantity lasts. The revised instructions and supply record need to agree, but the calculation should follow the approved plan. Do not let a dispensing quantity automatically determine a new duration or taper phase.
The response should state whether the proposal was accepted, declined or remains unresolved, and who made that decision. If accepted, identify the exact product and revised instructions. A message saying only “OK” can become detached from the product photograph or refer to an earlier proposal in the conversation.
Update the prescription through the clinic’s approved process and label its relationship to the earlier version. Tell the patient which copy applies and what to do with any older supply according to the clinician’s plan. Do not erase the original prescription or assume that changing the digital record changes a paper copy already held at the pharmacy.
Where a decision is urgent because treatment access is affected, route it through the clinic’s clinical escalation process. An administrative callback target is not a clinical guarantee that the patient can safely wait. Record the action agreed by the responsible professional rather than inventing a universal deadline for all medicines.
These are four separate states. A proposed alternative is a question. An authorised change records a decision. A dispensing confirmation describes what was supplied. Patient-reported use describes what happened afterward. A record can contain one without establishing the others.
If the patient has already received or taken a different product, obtain the actual identity and reported use for clinical review. Document the discrepancy and the resulting advice. Correcting the future prescription does not resolve any clinical consequences of earlier exposure, and a stock adjustment should not overwrite the patient’s history.
For partial supply, record the quantity actually received and the plan for the balance. Check whether another pharmacy, another pack or a revised clinical plan is involved. Keep those decisions explicit so that a later refill request is not mistaken for excess use or a completed course.
The following original outline keeps the question, evidence and answer together. It can be used on paper or in a clinic record. Distinguish a completed clarification handover from a resolved supply problem: the pharmacy may have acknowledged the decision while the patient’s access question remains open. Assigning an owner does not mean the outstanding work is complete.
A useful note names the exact accepted proposal instead of saying “alternative approved”. In a busy OPD, three photographs can arrive in the same message thread and an isolated “OK” can be attached to the wrong image. Retain the proposal-to-decision link, the original prescription and the complete replacement. Explain the changed line to the patient in their preferred language while keeping the verified medicine identity readable for the dispensing team.
In this example, P2 has been sent to the patient through the agreed contact route, but comprehension of the replacement is not yet confirmed at 11:30. The coordinator owns obtaining the patient’s account of the packet, routing any uncertainty to the clinician and confirming that the applicable instruction reaches any agreed family helper. The person forwarding a message is not automatically the person receiving or taking the medicine.
If another pharmacy offers the balance, transfer the current decision and confirmed supply history rather than restarting the request as though nothing was supplied. A different brand, formulation or strength from that pharmacy creates a new question; approval of C is not open permission to use any available product. Reconcile later confirmations against the seven outstanding tablets without silently changing the earlier five-tablet entry.
The clinician determines whether the access problem requires an immediate response or a revised plan. The timestamps below describe a fictional sequence, not a safe waiting interval. Do not promise that a partial quantity will bridge the gap without the actual regimen and assessment. Keep the access question open until the responsible professional’s decision and required communication are recorded, separately from whether the pharmacy ultimately locates stock.
Review recurring queries by the specific cause: an unavailable brand, an uncommon strength, unclear wording, a formulation mismatch or affordability. A count of “substitution requests” alone cannot show which problem the clinic should fix. A local pharmacy’s temporary stock position also should not silently redefine a shared medicine catalogue.
For a fictional week, suppose eight calls include three brand-availability questions, two strength changes, one release-formulation mismatch and two partial supplies. The total is eight queries, not eight approved substitutions. Track accepted, declined and unresolved decisions separately and examine why the same clarification recurs.
When evaluating Bractis, ask to trace one query from the original prescription to the decision and patient communication, with a different actual supply recorded afterward. Verify the current product’s capabilities directly. The purpose is to preserve a reliable clinical and supply history, not to claim an automated interchangeability engine.
A chemist proposes a similarly named product with the same printed strength. The clinic records the complete label and finds a different release formulation. Reception leaves the proposal pending rather than sending a generic approval. The clinician reviews the exact product and documents the decision, and the pharmacy and patient receive the applicable instructions. The case demonstrates why identity verification precedes arithmetic; it does not imply that the fictional products are interchangeable.
Use these prompts in your clinic’s own notes. Record the result, responsible person and next action for each item.
No. Formulation, release characteristics, route, additional ingredients, device and patient circumstances may matter. The proposed change needs appropriate professional review using the exact product information.
Reception can capture and route the query. Clinical approval must come from an appropriately authorised professional within the applicable rules and clinic process; collecting a product name does not confer that authority.
Do not assume so. Verify the exact product information, formulation and suitability, then obtain a reviewed instruction. A score line or another brand’s splitting instructions is not sufficient evidence for a different product.
Not automatically. Record the amount actually supplied and the agreed plan for obtaining the remainder or revising treatment. Any clinical change requires its own decision and instructions.
Establish the actual product and reported use for clinical review, document the advice and correct the applicable plan. A future catalogue or prescription edit cannot substitute for assessing what already happened.
The decision must state its scope. Identify the changed line and which other instructions remain current. A complete revised document can make that relationship clearer than a cropped medicine row. Do not infer that unrelated medicines have stopped or changed because one unavailable product was replaced.
Approval is specific to the reviewed product and plan. Share the current prescription and what has already been supplied, then reconcile the proposed balance. If the second pharmacy offers a different product, formulation or strength, obtain the appropriate new review rather than extending the first approval by assumption.
Updated on . This article combines the cited references with Bractis’s original workflow analysis and illustrative examples. Product capabilities depend on the configured scope. No independent clinical or legal review is claimed.
Official US HTML page directly read 28 October 2026; no publication or review date was visible in the retrieved page. Supports checking product-specific splitting information and not transferring suitability between brands. It does not establish Indian substitution authority. Individual product labels were not assessed, and no actual splitting method or conversion is prescribed here.
Official UK professional guidance directly read 28 October 2026. Published 17 December 2024; last updated 6 February 2025, with the update history identifying a podcast-link addition. Used narrowly for product-information and brand/formulation distinctions. Linked monographs, product labels and podcast were not reviewed. No manipulation instructions, Indian legal authority or real-product equivalence assessment is imported; the shortage case is original fictional analysis.
Verify unlisted medicines with a worked evidence trail for pack details, conflicting formulations, clinical review and catalogue decisions.
Reconcile insulin supply questions with a worked product-evidence table, five teaching observations and a handover separating issued plans from understanding.
Trace issued prescription corrections through version history, translated copies, queued outputs and recipient-specific communication.
Trace a fictional out-of-stock query through exact product comparison, professional review, revised instructions and confirmation of what the patient actually received.
Request a clinic demo